LGM Pharma

Executive Summary

LGM Pharma is a private, U.S.-based global supplier of active pharmaceutical ingredients (APIs), reference standards, and integrated contract development and manufacturing organization (CDMO) services. Founded in 2004 and headquartered in Las Vegas, the company supports pharmaceutical development from early-stage sourcing to commercial-scale manufacturing, with a strategic focus on generic drugs, 505(b)(2) products, and complex formulations. By leveraging a robust global supply chain network and investing in domestic manufacturing capabilities, LGM Pharma addresses the growing demand for reliable and high-quality API supply, particularly for specialty and complex molecules. The company’s growth strategy centers on expanding its U.S.-based manufacturing footprint to capture more market share in the generic and CDMO segments. While private and without disclosed funding or valuation, LGM Pharma’s emphasis on complex generics positions it well in a market characterized by supply chain vulnerabilities and increasing demand for near-shore production. Upcoming catalysts include the completion of its U.S. facility expansion, potential new API product introductions, and strategic partnerships that could enhance its commercial reach and operational scale.

Upcoming Catalysts (preview)

• Q3 2026Completion of U.S. manufacturing facility expansion70% success
• TBDLaunch of new complex generic API products65% success
• Q4 2026Strategic partnership or major CDMO contract win60% success